Spero Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Spero Therapeutics

16/05/2022 22:02

* Spero Therapeutics Inc  SPRO.OQ  reported a quarterly
adjusted
loss of $1.01​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 87 cents per share.
    * Revenue fell 71.7% to $2.07 million from a year ago; 
analysts
expected $2.57 million. 
    * The mean earnings estimate of analysts had risen by
about 18% in
the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Spero Therapeutics Inc shares had fallen by 80.3% this
quarter and lost 89.3% so far this year.
    * The company reported a quarterly loss of $32.83 million.
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $37.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 09:02 p.m.  ​All
figures in US dollars unless otherwise stated